{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-24-000040","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.287314+00:00","generated_at":"2026-05-30T01:28:36.819014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novavax Q3 revenue $85M, net loss $121M; FDA lifts clinical hold on combo vaccine","bullets":["Total revenue $85M (down from $187M YoY); net loss $121M vs $131M; cash $924M as of Sept 30.","FDA removed clinical hold on COVID-19-influenza combination and stand-alone influenza IND candidates.","Full-year 2024 revenue guidance cut to $650-700M from $700-800M; product sales now $175-225M.","Combined R&D/SG&A spend on track; targeting ~$500M in 2025 and ~$350M in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-24-000040","json":"https://secwatch.observer/filing/0001000694-24-000040.json","markdown":"https://secwatch.observer/filing/0001000694-24-000040.md","text":"https://secwatch.observer/filing/0001000694-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/0001000694-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/nvax-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:28:36.819014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}